

# CITATION REPORT

List of articles citing

**Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death**

**DOI: 10.1186/s12955-014-0140-1**

**Health and Quality of Life Outcomes, 2014, 12, 140.**

**Source:** <https://exaly.com/paper-pdf/58438060/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
36	Melanoma. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15003	51.1	283
35	A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. <i>Value in Health</i> , <b>2016</b> , 19, 1009-1015	3.3	20
34	Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1194-1202	2.2	63
33	Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 567-580.e2	3.5	18
32	How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 767-776	4.4	10
31	Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. <i>Quality of Life Research</i> , <b>2017</b> , 26, 1163-1176	3.7	24
30	Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 831-844	4.4	78
29	The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 33-41	4.4	39
28	Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal. <i>Value in Health</i> , <b>2017</b> , 20, 1065-1073	3.3	13
27	Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours - an analysis based on the CLARINET study. <i>Health and Quality of Life Outcomes</i> , <b>2017</b> , 15, 131	3	9
26	Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. <i>Journal of Medical Economics</i> , <b>2017</b> , 20, 140-150	2.4	35
25	Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2017</b> , 23, 184-194	1.9	40
24	The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. <i>European Journal of Health Economics</i> , <b>2018</b> , 19, 1163-1172	3.6	18
23	Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. <i>Journal of Medical Economics</i> , <b>2018</b> , 21, 1191-1205	2.4	44
22	Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. <i>Pharmacoeconomics - Open</i> , <b>2019</b> , 3, 377-390	2.1	9
21	Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy. <i>European Urology Oncology</i> , <b>2019</b> , 2, 565-571	6.7	12
20	Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 816-827	4.6	19

19	Combined cancer patient-reported symptom and health utility tool for routine clinical implementation: a real-world comparison of the ESAS and EQ-5D in multiple cancer sites. <i>Current Oncology</i> , <b>2019</b> , 26, e733-e741	2.8	3
18	Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA. <i>Immunotherapy</i> , <b>2019</b> , 11, 1463-1478	3.8	22
17	Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 337-343	3.6	5
16	Quality-of-life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , <b>2020</b> , 126, 611-618	6.4	4
15	Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 1507-1517	2.5	4
14	The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. <i>Journal of Medical Economics</i> , <b>2020</b> , 23, 967-977	2.4	6
13	What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node?. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 2913-2922	3.1	2
12	Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2033761	10.4	10
11	Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden. <i>Pharmacoeconomics</i> , <b>2021</b> , 39, 357-372	4.4	5
10	A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer. <i>PharmacoEconomics - Open</i> , <b>2021</b> , 5, 365-383	2.1	1
9	What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches. <i>Applied Health Economics and Health Policy</i> , <b>2021</b> , 19, 389-401	3.4	0
8	First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 788569	5.6	1
7	Large-Scale Population-Based Surveys Linked to Administrative Health Databases as a Source of Data on Health Utilities in Australia.. <i>Value in Health</i> , <b>2022</b> ,	3.3	0
6	Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. <i>Immunotherapy</i> ,	3.8	0
5	A systematic review of patient-reported outcome measures for advanced skin cancer patients.		0
4	Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. <b>2023</b> , 23,		0
3	Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective. 106002802211468		0
2	Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping. <b>2023</b> ,		0

- 1 Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

o